{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,2,10]],"date-time":"2024-02-10T00:18:43Z","timestamp":1707524323806},"reference-count":20,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2021,7,14]]},"DOI":"10.7759\/cureus.16398","type":"journal-article","created":{"date-parts":[[2021,7,15]],"date-time":"2021-07-15T06:47:45Z","timestamp":1626331665000},"source":"Crossref","is-referenced-by-count":0,"title":["Successful Treatment of Severe Gamma-Hydroxybutyric Acid Withdrawal Syndrome With Dantrolene"],"prefix":"10.7759","author":[{"given":"Anna Eveline","family":"R\u00f6ell","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dharmanand","family":"Ramnarain","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rama","family":"Kamal","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1016\/j.drugalcdep.2009.04.012","article-title":"Illicit gamma-hydroxybutyrate (GHB) and pharmaceutical sodium oxybate (Xyrem\u00ae): differences in characteristics and misuse","volume":"104","author":"Carter LP","year":"2009","unstructured":"Carter LP, Pardi D, Gorsline J, Griffiths RR. Illicit gamma-hydroxybutyrate (GHB) and pharmaceutical sodium oxybate (Xyrem\u00ae): differences in characteristics and misuse. Drug Alcohol Depend. 2009, 104:1-10. 10.1016\/j.drugalcdep.2009.04.012","journal-title":"Drug Alcohol Depend"},{"key":"ref2","article-title":"","author":"CAM: Risicoschatting Gamma-Hydroxyboterzuur 2011","year":"2011","unstructured":"CAM. Risicoschatting Gamma-Hydroxyboterzuur 2011: Bilthoven. 2011. https:\/\/www.rivm.nl\/bibliotheek\/digitaaldepot\/CAM_Risicoschatting_gamma_hydroxyboterzuur_2011.pdf."},{"key":"ref3","unstructured":"Trimbos Instituut. Cijfers drugs. gebruik en trends. Accessed: July 19, 2020: https:\/\/www.trimbos.nl\/kennis\/cijfers\/cijfers-drugs."},{"key":"ref4","article-title":"","author":"Van Laar M","year":"2016","unstructured":"Van Laar M, Van Ooyen-Houben M, Cruts A, Meijer R, Croes E. Nationale Drug Monitor: NDM Annual Report. Trimbos Instituut, Utrecht; 2016. https:\/\/www.trimbos.nl\/kennis\/feiten-cijfers-drugs-alcohol-roken\/ndm-monitoring-drugsgebruik-in-nederland."},{"key":"ref5","unstructured":"NICE Dataregister. https.\/\/stichting-nice.nl."},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1159\/000443173","article-title":"The neurobiological mechanisms of gamma-hydroxybutyrate dependence and withdrawal and their clinical relevance: a review","volume":"73","author":"Kamal RM","year":"2016","unstructured":"Kamal RM, van Noorden MS, Franzek E, Dijkstra BA, Loonen AJ, De Jong CA. The neurobiological mechanisms of gamma-hydroxybutyrate dependence and withdrawal and their clinical relevance: a review. Neuropsychobiology. 2016, 73:65-80. 10.1159\/000443173","journal-title":"Neuropsychobiology"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1007\/s40263-016-0402-z","article-title":"Pharmacological treatment in \u03b3-hydroxybutyrate (GHB) and \u03b3-butyrolactone (GBL) dependence: detoxification and relapse prevention","volume":"31","author":"Kamal RM","year":"2017","unstructured":"Kamal RM, van Noorden MS, Wannet W, Beurmanjer H, Dijkstra BA, Schellekens A. Pharmacological treatment in \u03b3-hydroxybutyrate (GHB) and \u03b3-butyrolactone (GBL) dependence: detoxification and relapse prevention. CNS Drugs. 2017, 31:51-64. 10.1007\/s40263-016-0402-z","journal-title":"CNS Drugs"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1186\/s12873-019-0224-7","article-title":"The healthcare costs of intoxicated patients who survive ICU admission are higher than non-intoxicated ICU patients: a retrospective study combining healthcare insurance data and data from a Dutch national quality registry","volume":"19","author":"van Beusekom I","year":"2019","unstructured":"van Beusekom I, Bakhshi-Raiez F, de Keizer NF, de Lange DW. The healthcare costs of intoxicated patients who survive ICU admission are higher than non-intoxicated ICU patients: a retrospective study combining healthcare insurance data and data from a Dutch national quality registry. BMC Emerg Med. 2019, 19:6. 10.1186\/s12873-019-0224-7","journal-title":"BMC Emerg Med"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMra044047","article-title":"\u03b3-hydroxybutyric acid","volume":"352","author":"Snead OC 3rd","year":"2005","unstructured":"Snead OC 3rd, Gibson KM. \u03b3-hydroxybutyric acid. N Engl J Med. 2005, 352:2721-2732. 10.1056\/NEJMra044047","journal-title":"N Engl J Med"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1017\/s1481803500010034","article-title":"Withdrawal from gamma-hydroxybutyrate, 1,4-butanediol and gamma-butyrolactone: a case report and systematic review","volume":"10","author":"Wojtowicz JM","year":"2008","unstructured":"Wojtowicz JM, Yarema MC, Wax PM. Withdrawal from gamma-hydroxybutyrate, 1,4-butanediol and gamma-butyrolactone: a case report and systematic review. CJEM. 2008, 10:69-74. 10.1017\/s1481803500010034","journal-title":"CJEM"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1097\/ADM.0000000000000214","article-title":"The effect of co-occurring substance use on gamma-hydroxybutyric acid withdrawal syndrome","volume":"10","author":"Kamal RM","year":"2016","unstructured":"Kamal RM, Dijkstra BA, Loonen AJ, De Jong CA. The effect of co-occurring substance use on gamma-hydroxybutyric acid withdrawal syndrome. J Addict Med. 2016, 10:229-235. 10.1097\/ADM.0000000000000214","journal-title":"J Addict Med"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1097\/ADM.0000000000000294","article-title":"Inpatient gamma-hydroxybutyrate detoxification: a case report describing day-to-day therapeutic management","volume":"11","author":"von Theobald L","year":"2017","unstructured":"von Theobald L, Rousselet M, Cholet J, Debar H, Boels D, Victorri-Vigneau C, Grall-Bronnec M. Inpatient gamma-hydroxybutyrate detoxification: a case report describing day-to-day therapeutic management. J Addict Med. 2017, 11:231-234. 10.1097\/ADM.0000000000000294","journal-title":"J Addict Med"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1016\/j.psym.2014.03.002","article-title":"A case series of pharmaceutical gamma-hydroxybutyrate in 3 patients with severe benzodiazepine-resistant gamma-hydroxybutyrate withdrawal in the hospital","volume":"56","author":"van Noorden MS","year":"2015","unstructured":"van Noorden MS, Kamal RM, Dijkstra BA, Mauritz R, de Jong CA. A case series of pharmaceutical gamma-hydroxybutyrate in 3 patients with severe benzodiazepine-resistant gamma-hydroxybutyrate withdrawal in the hospital. Psychosomatics. 2015, 56:404-409. 10.1016\/j.psym.2014.03.002","journal-title":"Psychosomatics"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1097\/ADM.0b013e3182236730","article-title":"Neuroleptic malignant syndrome-like reaction precipitated by antipsychotics in a patient with gamma-butyrolactone withdrawal","volume":"5","author":"Eiden C","year":"2011","unstructured":"Eiden C, Capdevielle D, Deddouche C, Boulenger JP, Blayac JP, Peyri\u00e8re H. Neuroleptic malignant syndrome-like reaction precipitated by antipsychotics in a patient with gamma-butyrolactone withdrawal. J Addict Med. 2011, 5:302-303. 10.1097\/ADM.0b013e3182236730","journal-title":"J Addict Med"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1093\/sleep\/27.7.1327","article-title":"A pilot study on the effects of sodium oxybate on sleep architecture and daytime alertness in narcolepsy","volume":"27","author":"Mamelak M","year":"2004","unstructured":"Mamelak M, Black J, Montplaisir J, Ristanovic R. A pilot study on the effects of sodium oxybate on sleep architecture and daytime alertness in narcolepsy. Sleep. 2004, 27:1327-1334. 10.1093\/sleep\/27.7.1327","journal-title":"Sleep"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1046\/j.0022-3042.2002.00780.x","article-title":"Evidence for a \u03b3-hydroxybutyrate (GHB) uptake by rat brain synaptic vesicles","volume":"80","author":"Muller C","year":"2002","unstructured":"Muller C, Viry S, Miehe M, Andriamampandry C, Aunis D, Maitre M. Evidence for a \u03b3-hydroxybutyrate (GHB) uptake by rat brain synaptic vesicles. J Neurochem. 2002, 80:899-904. 10.1046\/j.0022-3042.2002.00780.x","journal-title":"J Neurochem"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1016\/j.neuroscience.2014.07.056","article-title":"Regional Fos-expression induced by \u03b3-hydroxybutyrate (GHB): comparison with \u03b3-butyrolactone (GBL) and effects of co-administration of the GABAB antagonist SCH 50911 and putative GHB antagonist NCS-382","volume":"277","author":"van Nieuwenhuijzen PS","year":"2014","unstructured":"van Nieuwenhuijzen PS, McGregor IS, Chebib M, Hunt GE. Regional Fos-expression induced by \u03b3-hydroxybutyrate (GHB): comparison with \u03b3-butyrolactone (GBL) and effects of co-administration of the GABAB antagonist SCH 50911 and putative GHB antagonist NCS-382. Neuroscience. 2014, 277:700-715. 10.1016\/j.neuroscience.2014.07.056","journal-title":"Neuroscience"},{"key":"ref18","article-title":"[Neuroleptic malignant syndrome: a life-threatening complication that can be treated effectively]","volume":"150","author":"van Waarde JA","year":"2006","unstructured":"van Waarde JA, Muller ME, Verweg B. [Neuroleptic malignant syndrome: a life-threatening complication that can be treated effectively]. Ned Tijdschr Geneeskd. 2006, 150:2517-2520.","journal-title":"Ned Tijdschr Geneeskd"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.1016\/j.neuroscience.2010.02.009","article-title":"Calcium and cAMP signaling induced by gamma-hydroxybutyrate receptor(s) stimulation in NCB-20 neurons","volume":"167","author":"Coune P","year":"2010","unstructured":"Coune P, Taleb O, Mensah-Nyagan AG, Maitre M, Kemmel V. Calcium and cAMP signaling induced by gamma-hydroxybutyrate receptor(s) stimulation in NCB-20 neurons. Neuroscience. 2010, 167:49-59. 10.1016\/j.neuroscience.2010.02.009","journal-title":"Neuroscience"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.1007\/s12028-008-9133-4","article-title":"Dantrolene: mechanisms of neuroprotection and possible clinical applications in the neurointensive care unit","volume":"10","author":"Muehlschlegel S","year":"2009","unstructured":"Muehlschlegel S, Sims JR. Dantrolene: mechanisms of neuroprotection and possible clinical applications in the neurointensive care unit. Neurocrit Care. 2009, 10:103-115. 10.1007\/s12028-008-9133-4","journal-title":"Neurocrit Care"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/64385-successful-treatment-of-severe-gamma-hydroxybutyric-acid-withdrawal-syndrome-with-dantrolene","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,2,9]],"date-time":"2024-02-09T19:32:43Z","timestamp":1707507163000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/64385-successful-treatment-of-severe-gamma-hydroxybutyric-acid-withdrawal-syndrome-with-dantrolene"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,7,14]]},"references-count":20,"URL":"https:\/\/doi.org\/10.7759\/cureus.16398","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2021,7,14]]}}}